Compound Evidence File
#EC-2026-0200
SS-31 (Elamipretide) Raw
Filed under Raw Materials. The bureau holds 119 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
40 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 10.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 3 May 2026 | 14 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 19 Mar 2026 | 21 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 19 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Nov 2025 | 17 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 10.0 | 10.0 | 17 Feb 2026 | 20 Apr 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Jan 2026 | 15 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 26 Feb 2026 | 9 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 10.0 | 10.0 | 25 Feb 2026 | 16 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 16 Feb 2026 | 12 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Apr 2026 | 4 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Nov 2025 | 5 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Jan 2026 | 8 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 11 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 5 Jan 2026 | 13 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 11 Nov 2025 | 26 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 8 May 2026 | 18 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Feb 2026 | 25 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 20 May 2026 | 16 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Feb 2026 | 4 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Apr 2026 | 25 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 9.0 | 8.1 | 9.8 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.9 | 6.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 1 | 8.9 | 8.9 | 8.9 | 7 May 2025 | 7 May 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 8.7 | 8.7 | 8.7 | 27 Feb 2025 | 27 Feb 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.6 | 7.6 | 9.3 | 25 May 2026 | 25 May 2026 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 8.6 | 8.6 | 8.6 | 16 Mar 2025 | 16 Mar 2025 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 8.6 | 8.6 | 8.6 | 3 Jul 2025 | 3 Jul 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 8.3 | 8.3 | 8.3 | 13 Feb 2025 | 13 Feb 2025 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 8.3 | 8.3 | 8.3 | 27 Feb 2025 | 27 Feb 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 7.9 | 6.6 | 8.9 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 7.9 | 7.3 | 8.7 | 24 May 2026 | 24 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 4 | 6.8 | 4.7 | 10.0 | 6 May 2025 | 24 May 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 6.6 | 6.6 | 6.6 | 9 Jun 2025 | 9 Jun 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 6.4 | 6.4 | 6.4 | 16 Mar 2025 | 16 Mar 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 6.1 | 6.1 | 6.1 | 6 May 2025 | 6 May 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 5.0 | 5.0 | 5.0 | 28 Mar 2025 | 28 Mar 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.0 | 0.0 | 0.0 | 11 Jun 2025 | 11 Jun 2025 |
Open any subject to view the batch-level evidence for SS-31 (Elamipretide) Raw alone.